| P50 | author | Jennifer Martin | Q44551189 |
| P2093 | author name string | Geert Jan Groeneveld | |
| P2860 | cites work | The neurobiology of antiepileptic drugs | Q28267900 |
| | International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ | Q28298445 |
| | Cannabis, cannabidiol, and epilepsy--from receptors to clinical response | Q34441767 |
| | Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 |
| | Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. | Q35659141 |
| | Molecular Targets of Cannabidiol in Neurological Disorders | Q36157649 |
| | Achieving the World Health Organization's vision for clinical pharmacology | Q36802085 |
| | Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience | Q39007125 |
| | Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 |
| | Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol | Q41808396 |
| | Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability | Q44208964 |
| | Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? | Q47787065 |
| | Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. | Q48415758 |
| | Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. | Q51749647 |
| | Statistics in medicine--reporting of subgroup analyses in clinical trials. | Q51899945 |
| | Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. | Q53781287 |
| | Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. | Q53835626 |
| | Mechanisms of Action of Antiepileptic Drugs | Q56568067 |
| | Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome | Q57905612 |
| | Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 |
| | Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q62868237 |
| | Therapeutic use of medicinal cannabis in difficult to manage epilepsy | Q90831121 |
| | Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency | Q90968838 |
| | Care and concern with cannabinoids used therapeutically | Q91095982 |
| P433 | issue | 2 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 189-191 | |
| P577 | publication date | 2019-07-10 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Parasitic pharmacology: A plausible mechanism of action for cannabidiol | |
| P478 | volume | 86 | |